Westmount Partners LLC Decreases Holdings in Pfizer Inc. (NYSE:PFE)

Westmount Partners LLC cut its stake in shares of Pfizer Inc. (NYSE:PFE) by 9.9% in the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The fund owned 14,891 shares of the biopharmaceutical company’s stock after selling 1,643 shares during the period. Westmount Partners LLC’s holdings in Pfizer were worth $395,000 as of its most recent SEC filing.

A number of other hedge funds have also added to or reduced their stakes in the stock. GHP Investment Advisors Inc. increased its stake in shares of Pfizer by 5.2% in the 2nd quarter. GHP Investment Advisors Inc. now owns 12,589 shares of the biopharmaceutical company’s stock worth $352,000 after purchasing an additional 620 shares in the last quarter. Parallel Advisors LLC increased its stake in shares of Pfizer by 19.1% in the 2nd quarter. Parallel Advisors LLC now owns 108,180 shares of the biopharmaceutical company’s stock worth $3,027,000 after purchasing an additional 17,370 shares in the last quarter. Thoroughbred Financial Services LLC grew its stake in shares of Pfizer by 102.9% during the second quarter. Thoroughbred Financial Services LLC now owns 32,173 shares of the biopharmaceutical company’s stock valued at $900,000 after buying an additional 16,313 shares during the last quarter. Oppenheimer Asset Management Inc. grew its stake in shares of Pfizer by 9.0% during the second quarter. Oppenheimer Asset Management Inc. now owns 328,170 shares of the biopharmaceutical company’s stock valued at $9,182,000 after buying an additional 27,178 shares during the last quarter. Finally, Envestnet Asset Management Inc. grew its stake in shares of Pfizer by 2.4% during the second quarter. Envestnet Asset Management Inc. now owns 10,260,067 shares of the biopharmaceutical company’s stock valued at $287,077,000 after buying an additional 238,850 shares during the last quarter. 68.36% of the stock is currently owned by hedge funds and other institutional investors.

Insider Activity at Pfizer

In other Pfizer news, Director Scott Gottlieb purchased 1,000 shares of the company’s stock in a transaction on Wednesday, October 30th. The stock was acquired at an average price of $28.24 per share, for a total transaction of $28,240.00. Following the completion of the purchase, the director now directly owns 10,000 shares in the company, valued at approximately $282,400. The trade was a 11.11 % increase in their position. The purchase was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. 0.06% of the stock is owned by insiders.

Analysts Set New Price Targets

Several analysts have recently commented on the company. Citigroup started coverage on Pfizer in a report on Friday, October 25th. They set a “neutral” rating and a $30.00 price objective for the company. Sanford C. Bernstein started coverage on Pfizer in a research note on Thursday, October 17th. They issued a “market perform” rating and a $32.00 target price for the company. Truist Financial reduced their target price on Pfizer from $36.00 to $32.00 and set a “buy” rating for the company in a research note on Wednesday, December 18th. Wolfe Research began coverage on Pfizer in a research note on Friday, November 15th. They issued an “underperform” rating and a $25.00 target price for the company. Finally, Evercore ISI raised Pfizer to a “strong-buy” rating in a research report on Wednesday, October 30th. One equities research analyst has rated the stock with a sell rating, eight have issued a hold rating, six have given a buy rating and two have issued a strong buy rating to the company’s stock. Based on data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and a consensus price target of $32.00.

Pfizer Price Performance

Pfizer stock traded down $0.09 during midday trading on Monday, reaching $26.63. The company had a trading volume of 17,097,867 shares, compared to its average volume of 32,872,508. The company has a market capitalization of $150.91 billion, a P/E ratio of 35.99, a P/E/G ratio of 0.63 and a beta of 0.64. Pfizer Inc. has a 12-month low of $24.48 and a 12-month high of $31.54. The firm’s fifty day simple moving average is $26.18 and its 200-day simple moving average is $28.04. The company has a debt-to-equity ratio of 0.63, a current ratio of 1.00 and a quick ratio of 0.73.

Pfizer (NYSE:PFE) last released its earnings results on Tuesday, October 29th. The biopharmaceutical company reported $1.06 earnings per share for the quarter, topping analysts’ consensus estimates of $0.64 by $0.42. Pfizer had a net margin of 7.07% and a return on equity of 16.28%. The business had revenue of $17.70 billion for the quarter, compared to analyst estimates of $14.92 billion. During the same period last year, the company posted ($0.17) EPS. The business’s revenue was up 31.2% on a year-over-year basis. As a group, equities analysts anticipate that Pfizer Inc. will post 2.95 EPS for the current year.

Pfizer Increases Dividend

The company also recently declared a quarterly dividend, which will be paid on Friday, March 7th. Stockholders of record on Friday, January 24th will be given a dividend of $0.43 per share. This represents a $1.72 annualized dividend and a dividend yield of 6.46%. The ex-dividend date is Friday, January 24th. This is a positive change from Pfizer’s previous quarterly dividend of $0.42. Pfizer’s payout ratio is presently 232.43%.

Pfizer Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.